Human Kallikrein 13 Antibody
R&D Systems, part of Bio-Techne | Catalog # MAB2625
Key Product Details
Species Reactivity
Applications
Label
Antibody Source
Product Specifications
Immunogen
Val19-Ile262
Accession # Q9UKR3
Specificity
Clonality
Host
Isotype
Endotoxin Level
Applications for Human Kallikrein 13 Antibody
Immunoprecipitation
Sample: Conditioned cell culture medium spiked with Recombinant Human Kallikrein 13 (Catalog # 2625-SE), see our available Western blot detection antibodies
Western Blot
Sample: Recombinant Human Kallikrein 13 (Catalog # 2625-SE)
Reviewed Applications
Read 1 review rated 5 using MAB2625 in the following applications:
Formulation, Preparation, and Storage
Purification
Reconstitution
Formulation
Shipping
Stability & Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: Kallikrein 13
Human tissue Kallikrein 13 (hK13) is a member of the human tissue kallikrein family. The gene encoding for rhK13 is termed KLK13 and it resides on chromosome 19q13.3-4 along with fourteen other members of the family. KLK13 spans about 8.7 kb genomic DNA and the longest transcript is 831 bp, encoding for a protein of 277 amino acids (1). Another five shorter splice variants have also been identified. They are specifically expressed in the testicular tissue and encode for five truncated forms of hK13 (2). Due to the aspartic acid residue in the substrate binding pocket, the enzymatic activity of hK13 is predicted be trypsin-like. It has been shown that recombinant hK13 produced in yeast can cleave synthetic peptides after the arginine residue and some extracellular matrix components (3). However, its exact physiological substrates and functions remain obscure. Despite the lack of knowledge on the physiological function of hK13, several studies have demonstrated that hK13 is implicated with cancer of the breast and ovary and it can serve as a favorable prognostic biomarker for these malignancies (4, 5). The 277 amino acid hKLK13 precursor consists of a signal peptide (residues 1 to 18), a pro peptide (residues 19 to 25) and an active protein (residues 26 to 277). The amino acid sequence of hKLK13 is 84%, 81%, and 80% identical to that of canine, mouse and rat.
References
- Yousef, G.M. et al. (2000) J. Biol. Chem. 275:11891.
- Chang, A. et al. (2001) Anticancer Res. 21:3147.
- Kapadia, C. et al. (2004) Biochem. Biophys. Res. Commun. 323:1084.
- Chang, A. et al. (2002) Br. J. Cancer. 86:1457.
- Scorilas, A. et al. (2004) J. Clin. Oncol. 22:678.
Alternate Names
Entrez Gene IDs
Gene Symbol
UniProt
Additional Kallikrein 13 Products
Product Documents for Human Kallikrein 13 Antibody
Product Specific Notices for Human Kallikrein 13 Antibody
For research use only